Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03618550 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

StatusRecruiting
PhasePhase 2
Started2018-08-01
View on ClinicalTrials.gov ↗
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

Amendment history 3 changes detected by DataLookout

2026-07-16
Primary endpoint(s) modified
WasComplete response rate (part 1)
NowAssess freedom from disease at 5 years (part 3), Complete response rate (part 1)
2026-07-16
Primary completion pushed: 2026-08 → 2027-08
2026-07-16
Completion pushed: 2026-08 → 2027-08
Trial Details
NCT Number NCT03618550
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Enrollment 257 participants
Start Date 2018-08-01
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-07